(Q46200201)

20 December 2017

title

Diagnosis and treatment of celiac disease (English)

1 reference

20 December 2017

author name string

L M Sollid

series ordinal

1

1 reference

20 December 2017

K E A Lundin

series ordinal

2

1 reference

20 December 2017

language of work or name

1 reference

29 October 2008

1 reference

20 December 2017

published in

Mucosal Immunology

1 reference

20 December 2017

volume

2

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

3-7

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1038/mi.2008.74

exact match

0 references

cites work

Coeliac disease: dissecting a complex inflammatory disorder

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Celiac disease: pathogenesis of a model immunogenetic disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Diagnosis of celiac disease in clinical practice: physician's alertness to the condition essential

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Identification of tissue transglutaminase as the autoantigen of celiac disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Immunoglobulin A autoantibodies against transglutaminase 2 in the small intestinal mucosa predict forthcoming coeliac disease.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Latent coeliac disease or coeliac disease beyond villous atrophy?

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

B cell epitopes of gliadin

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Accuracy of testing for antibodies to synthetic gliadin-related peptides in celiac disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Combination testing for antibodies in the diagnosis of coeliac disease: comparison of multiplex immunoassay and ELISA methods.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Self transglutaminase-based rapid coeliac disease antibody detection by a lateral flow method.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Production of antiendomysial antibodies after in-vitro gliadin challenge of small intestine biopsy samples from patients with coeliac disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Tetramer visualization of gut-homing gluten-specific T cells in the peripheral blood of celiac disease patients

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Celiac disease genetics: current concepts and practical applications

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Analysis and clinical effects of gluten in coeliac disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Future therapeutic options for celiac disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Cinnamoyl inhibitors of tissue transglutaminase.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with celiac disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Newly identified genetic risk variants for celiac disease related to the immune response

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.74

7 January 2021

Identifiers

DOI

10.1038/MI.2008.74

1 reference

20 December 2017

1 reference

20 December 2017